Arabic Arabic English English French French German German
dark

Aceragen Launches with Acquisition of Enzyvant‘s Investigational Therapy for Farber Disease and $35 Million Product Financing with NovaQuest

Aceragen, Inc. announced the acquisition of Enzyvant’s RVT-801, an investigational enzyme replacement therapy for acid ceramidase deficiency presenting as Farber disease, a lysosomal storage disease with a unique, severe inflammatory phenotype for which no disease-specific therapy exists. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Tetra Bio-Pharma Granted a Drug Establishment License to Distribute REDUVO Soft Gel Capsules in Canada

Next Post

The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependence

Related Posts
Total
0
Share